harnessing novel t cell systems to extend the promise of immunotherapy
Company profile
Ticker
TCRX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
TScan Securities Corporation ...
IRS number
825282075
TCRX stock data
Latest filings (excl ownership)
S-3
Shelf registration
6 Mar 24
S-8
Registration of securities for employees
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
6 Mar 24
8-K
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
29 Jan 24
8-K
Regulation FD Disclosure
11 Dec 23
8-K
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
7 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
Latest ownership filings
SC 13G/A
K2 HealthVentures Equity Trust LLC
14 Feb 24
SC 13G/A
GV 2017, L.P.
9 Feb 24
SC 13G/A
Pitango HealthTech Fund I, L.P.
8 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4
Jason Amello
2 Feb 24
3
Jason Amello
2 Feb 24
4
TIMOTHY J BARBERICH
21 Dec 23
4
Barbara Klencke
18 Dec 23
4
Keith Woods
8 Dec 23
3
Keith Woods
8 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 160.22 mm | 160.22 mm | 160.22 mm | 160.22 mm | 160.22 mm | 160.22 mm |
Cash burn (monthly) | 17.88 mm | (no burn) | 8.25 mm | 7.56 mm | (no burn) | 4.47 mm |
Cash used (since last report) | 106.97 mm | n/a | 49.35 mm | 45.24 mm | n/a | 26.72 mm |
Cash remaining | 53.25 mm | n/a | 110.88 mm | 114.99 mm | n/a | 133.50 mm |
Runway (months of cash) | 3.0 | n/a | 13.4 | 15.2 | n/a | 29.9 |
Institutional ownership, Q2 2023
89.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 7 |
Closed positions | 7 |
Increased positions | 7 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 69.56 bn |
Total shares | 39.16 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lynx1 Capital Management | 5.22 mm | $13.06 bn |
EcoR1 Capital | 5.00 mm | $12.50 bn |
Biotechnology Value Fund L P | 4.41 mm | $14.08 mm |
Adage Capital Partners GP, L.L.C. | 4.00 mm | $10.00 bn |
BVF | 2.99 mm | $7.47 bn |
Baker Bros. Advisors | 2.78 mm | $6.96 bn |
K2 HealthVentures Equity Trust | 2.10 mm | $6.93 mm |
Vanguard | 1.36 mm | $3.40 bn |
Longwood Fund IV | 1.28 mm | $5.76 mm |
BLK Blackrock | 1.26 mm | $3.16 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Feb 24 | Jason Amello | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 5.15 | 750,000 | 3.86 mm | 750,000 |
19 Dec 23 | Barberich Timothy J | Voting Common Stock | Buy | Acquire P | No | No | 4.9685 | 317 | 1.58 k | 67,027 |
18 Dec 23 | Barberich Timothy J | Voting Common Stock | Buy | Acquire P | No | No | 4.8866 | 28,830 | 140.88 k | 66,710 |
14 Dec 23 | Barbara Klencke | Voting Common Stock | Buy | Acquire P | No | No | 5.08 | 5,000 | 25.40 k | 30,000 |
6 Dec 23 | Keith Woods | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 6.74 | 17,500 | 117.95 k | 17,500 |
News
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
22 Mar 24
Barclays Maintains Overweight on TScan Therapeutics, Raises Price Target to $9
7 Mar 24
HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $15 Price Target
7 Mar 24
TScan Therapeutics: Q4 Earnings Insights
6 Mar 24
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $9 Price Target
1 Feb 24
Press releases
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
28 Feb 24
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
14 Feb 24
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
6 Feb 24
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
18 Jan 24